Arno Therapeutics, Inc. HomeAbout UsPipelineInvestor RelationsContact Us
Creating the next generation of cancer treatments
About Us
Mission Management Board of Directors


Glenn Mattes
President and Chief Executive Officer

Mr. Mattes has been Arno's President and Chief Executive Officer since April 2011. He has over 25 years of pharmaceutical commercialization and general management experience. Before joining Arno, Mr. Mattes was President of Tibotec Therapeutics, a Johnson & Johnson company focused on oncology and virology therapeutics, where he led the organization responsible for the development, marketing and sales of novel antiretroviral compounds in North America. Under his leadership, Tibotec successfully launched Johnson & Johnson's first two U.S. HIV/AIDS products. In 2008, Mr. Mattes was appointed to the President's Advisory Council on HIV/AIDS (PACHA) by the U.S. Secretary of Health and Human Services to provide counsel on both domestic and global health and treatment issues. Prior to running Tibotec, Mr. Mattes served as Vice President of Worldwide Commercial Operations at Centocor, where he played a critical role in defining Centocor's business strategy and was responsible for the organization's sales and marketing strategy supporting the introduction of Remicade®. Prior to joining Centocor, Mr. Mattes worked at Rhone Poulenc Rorer (RPR) (now Aventis), where he held positions of increasing responsibility, including President of RPR Canada and Vice President of Advanced Therapeutics and Oncology, North America, where he was responsible for the successful launch of Taxotere® and Lovenox®.

Alexander Zukiwski, MD
Vice President and Chief Medical Officer

Dr. Zukiwski is responsible for leading the clinical development and regulatory affairs teams supporting Arnoís current and future pipeline of innovative cancer therapies. He has more than 15 years of experience in global oncology drug development and has supported the clinical evaluation and registration of many successful therapeutic agents, including Taxotere®, Xeloda®, Procrit®/Eprex®, Velcade®, Yondelis® and Doxil®. Dr. Zukiwski was most recently Executive Vice President, Clinical Research, and Chief Medical Officer at MedImmune, Inc. where the organization he led was responsible for developing and implementing MedImmune's clinical research, medical affairs and safety strategies. Prior to joining MedImmune, Dr. Zukiwski held medical affairs and clinical development positions of increasing responsibility at Johnson & Johnson Pharmaceutical Research & Development, LLC (JJPRD), Centocor and Ortho Biotech, including serving as therapeutic area head for oncology and acting head of oncology research and development. Before joining Johnson & Johnson, Dr. Zukiwski held clinical oncology positions at Hoffmann-LaRoche, Glaxo Wellcome and Rhone- Poulenc Rorer. He received a bachelorís degree in pharmacy from the University of Alberta and a Doctor of Medicine degree from the University of Calgary and conducted post- graduate training at St. Thomas Hospital Medical Center in Akron, Ohio and the University of Texas, M.D. Anderson Cancer Center.

Stefan Proniuk, PhD
Vice President Product Development

Dr. Proniuk has over 15 years of experience in pharmaceutical product development. In his current role, he is responsible for the preclinical, chemical and pharmaceutical development of Arno's portfolio. Dr. Proniuk has extensive development experience across multiple therapeutic areas and dosage forms and has participated in the submission of 13 INDs/CTAs/IMPDs and 2 NDAs. Prior to joining Arno, he was the Senior Manager of Pharmaceutical Technologies at Neurocrine Biosciences (2002-2008) where he was responsible for overseeing development programs from Phase I to commercial launch and was also appointed to lead the pharmaceutical sciences group. Previously, Dr. Proniuk worked as a scientist at Cima Labs (2001-2002) on the development and scale-up of orally disintegrating tablet formulations (Niravam®, Triaminic®). Dr. Proniuk holds a Ph.D. degree in Pharmaceutical Sciences from the University of Arizona, an M.B.A. from San Diego State University and a Diplom (FH) in Chemical Engineering from the University of Applied Sciences Isny in Germany.

Arno Therapeutics, Inc.
200 Route 31 North
Suite 104
Flemington, NJ 08822

(862) 703-7170 Main
(908) 237-0071 Fax